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The present work aims at preparing aqueous suspension of Solid lipid Nanoparticles containing Chitosan (CT) which
is a biopolymer that exhibits a number of interesting properties which include controlled drug delivery.
Carbamezapine (CBZ) is a lipophilic drug which shows it antiepileptic activity by inactivating sodium channels. The
solid lipid Nanoparticles (SLN) of Chitosan-CBZ were prepared by using solvent injection method using ethanol as
organic solvent. The prepared SLN formulations exhibited high encapsulation efficiency, high physical stability. The
drug incorporated SLNs have demonstrated that the controlled release patterns of the drug for prolonged period.
The prepared SLNs were characterized for surface morphology by SEM analysis, entrapment efficiency, zeta
potential, FTIR, DSC and In-vitro diffusion studies. The hydrodynamic mean diameter and zeta potential were 168.7
±1.8 nm and −28.9 ±2.0 mV for SLN-chitosan-CBZ respectively. Therefore chitosan-SLN can be good candidates to
encapsulate CBZ and to increase its therapeutic efficacy in the treatment of Epilepsy.
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Solid Lipid Nanoparticles (SLN) mainly comprise lipids
that are in solid phase at the room temperature and sur-
factants for emulsification, the mean diameters of which
range from 50 to 1000nm for colloid drug delivery appli-
cations [1]. SLNs offer unique properties such as small
size, large surface area, high drug loading, the inter-
action of phases at the interfaces, and are attractive for
their potential to improve performance of pharmaceuti-
cals, neutraceuticals and other materials [2]. The typical
methods of preparing SLNs include spray drying [3],
high shear mixing [4], ultra-sonication [5,6], and high
pressure homogenization (HPH) [7,8]. Advantages of
SLN are the use of physiological lipids, the avoidance of
organic solvents in the preparation process, and a wide
potential application spectrum (dermal, oral and intra-
venous). Additionally, improved bioavailability, protec-
tion of sensitive drug molecules from the environment
(water, light) and controlled and/or targeted drug release
[9-11], improved stability of pharmaceuticals, feasibilities
of carrying both lipophilic and hydrophilic drugs and
most lipids being biodegradable [12,13]. SLNs possess a* Correspondence: rahulnair2476@gmail.com
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reproduction in any medium, provided the orbetter stability and ease of upgradability to production
scale as compared to liposomes. This property may be
very important for many modes of targeting. SLNs form
the basis of colloidal drug delivery systems, which are
biodegradable and capable of being stored for at least
one year. Chitosan (CT) is a biopolymer that has been
widely used in the pharmaceutical field since it exhibits
a number of interesting properties with wide range of
pharmaceutical applications. A chitosan-based transport
system has been developed for overcoming the Blood
brain barrier [14]. The mechanism of action of carba-
mazepine is stabilizes the inactivated state of sodium
channels, meaning that fewer of these channels are avail-
able to subsequently open, making brain cells less excit-
able carbamazepine has also been shown to potentiate
GABA receptors made up of α1, β2 and γ2 subunits
[15]. The present work aims to combine the advantages
of SLN with the biological properties of chitosan in im-
proving the antiepileptic property of lipophilic drug like




Carbamazepine was purchased from Yarrow chemicals
Ltd. (Mumbai, India). Phospholipon R 80 H was a gift. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 FTIR spectra CBZ (A), Chitosan (B) Tristearin (C), Physical mixture of CBZ and Tristearin (D) and CBZ SLN (E).
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from Central fisheries research Institute (Cochin). Tris-
tearin was procured from TCI Chemicals (India) Pvt.
Ltd. All other reagents used in this study were of ana-
lar grade.
Method of preparation of SLN dispersion
Preparation of CBZ loaded SLNs and the process of
optimization
The CT-CBZ SLNs were prepared by using solvent in-
jection method using ethanol as organic solvent. Tris-
tearin, solubilized CT phospholipon R 80 H and drug is
dissolved in the ethanol in definite ratio and warmed to
70°C. To the phosphate buffer solution (pH 7.4) aTable 1 FTIR interpretation of CBZ SLN comparative to pure d
Functional group Drug SLN formulation
N-H stretch 3464 cm-1 3444.8 cm-1
C = 0 stretch 1677 cm-1 1635.64 cm-1
Aromatic C-H stretch 3080.75 cm-1 Absent
C = C stretch 1605 cm-1 1635.64,1558.48 cm-1
CN 1384.89 cm-1 1373.32 cm-1
CHO aldehydic group Absent 1732.80 cm-1
Methylene C-H asym stretch Absent Absent
Polymeric Absent 3444.87 cm-1
O-H stretch 3419.97 cm-1definite amount of tween 80 is added to prepare aqueous
phase and kept for stirring which is maintain at 70°C.
The organic phase was added drop wise with stirring to
the pre warmed aqueous solution with the help of hypo-
dermic needle. The mixture was then sonicated for vary-
ing time to obtain nanoparticles. The optimum
parameters i.e. tween 80 concentrations in definite ratio
and maximum sonication time resulted in maximum en-
trapment efficiency and controlled release were used for
the preparation of SLN using similar method [17,18].
Three formulations were prepared by using different
concentrations of tween 80 and sonication time to deter-
mine the effect of surfactant and sonication time on the
potency of the SLNs.rug physical mixture and polymers
Physical mixture Tristearin Phospholipon 80 H
3464.15 cm-1 Absent Absent
1678.07 cm-1 Absent Absent
2954.95 cm-1 2954.95 cm-1 2954.95 cm-1
1604.77 cm-1 Absent Absent
1384.89 cm-1 Absent Absent
1735.93 cm-1 1728.22 cm-1 1725.92 cm-1
2916.37 cm-1 2914.44 cm-1 2916.37 cm-1
3280.92 cm-1 Absent 3398.57 cm-1
3377.26 cm-1
3281.93 cm-1
Figure 2 DSC thermograms of CBZ (A), Tristearin (B), Physical mixture of CBZ and Tristearin (C) and CBZ SLN D.
Figure 3 CBZ loaded SLN SEM photograph.
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Table 2 Free drug content, Total drug content and %EE
of SLN formulationsange





1 F1 10.2 20.136 48.84
2 F2 23.4 34.86 32.87
3 F3 8.6 25.8 66.7
Table 3 Zeta potential ,particle size and polydispersity






F1 168.7 ± 1.8 nm 0.206 −28.9 ± 2.0 mV
F2 187.5 ± 2.8 nm 0.219 −27.60 ± 1.8 mV
F3 154.0 ± 1.5 nm 0.309 −32.12 ± 1.4 mV
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Fourier Transform infrared (FTIR) spectroscopic
analysis The FTIR spectra of CBZ, tristearin, phospholi-
pon 80 H, CT CBZ loaded SLNs and physical mixture of
lipids and drug in 1:1 ratio were recorded using FTIR
spectrophotometer in the range of 4000–650 cm-1 [19].
Measurement of particle size, polydispersity index and zeta
potential
Particle size distribution of CBZ loaded SLNs was deter-
mined by laser scanning technique using Malvern instru-
ment after appropriate dilution with distilled water. The
mean particle size, polydispersity index and zeta poten-
tial were calculated for each formulation maintained at
25°C and polydispersity index will measure the size dis-
tribution of nanoparticles population [20].
Scanning electron microscopy (SEM)
The SEM analysis of prepared SLN was performed for
morphological studies. The formulations are poured in to
circular aluminium stubs using double adhesive tape, and
coated with gold in HUS -5 GB vacuum evaporator , and
observed in Hitachi S-3000 N SEM at an acceleration
voltage of 10 Kv and a magnification of 5000X [21].
Differential scanning calorimetry (DSC)
DSC analysis was performed in order to investigate the
melting and recrystallization behaviour of crystalline
materials like SLNs. The samples were sealed in alumin-
ium pans and measurements were recorded using DSC
instrument. The samples were heated from 25 to 200°CFigure 4 CBZ SLN F1 Size distribution chart.at a heating rate of 100°C /min under nitrogen atmos-
phere [22].Total drug content
From the prepared SLN formulation 1 ml of suspension
is dissolved in the 10 ml of pH7.4 phosphate buffer solu-
tion (PBS) and ethanol mixture. The amount of carba-
mazepine was determined using UV spectrophotometer
at 285 nm. The placebo formulation prepared similarly
to drug loaded SLN is used as blank. The total drug con-
tent was calculated.Entrapment efficiency (EE)
The prepared SLN dispersion was centrifuged with
15000 rpm speed for 30 min at 0°C using REMI cooling
centrifuge. The free drug content is calculated with
using of equation, EE = {total drug content-free drug
content/ total drug content} X 100 from the supernatant
portion.In-vitro diffusion studies
The modified Franz diffusion cell at 37°C which is fitted
with a dialysis membrane having a molecular weight cut
off 350 Da was used for study. The membrane was
soaked in boiling distilled water for 12 hours before
mounting to Franz diffusion cell. SLN dispersion 2 ml
was placed in to the donor compartment and the 20 ml
of PBS is used to fill receptor compartment. With one
hour interval 1 ml of sample was withdrawn and ana-
lysed using UV spectrophotometer at 285 nm [23].
Figure 5 Comparative release profile of CBZ SLN in 7.4 PBS for F1-F3.
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Experimental animals
Male albino rats of Wistar strain weighing 150 – 200 g
were used for the study. They were housed in polypro-
pylene cages and maintained under standard laboratory
conditions with a 12–12 h light–dark cycle and as wellFigure 6 The various stages in MES induced seizures.as free access to standard rat pellet diet (Lipton, India
Ltd.) and drinking water. They were acclimatized to la-
boratory conditions for 10 days before starting the ex-
periment. The experimental protocol was approved by
the institutional animal ethical committee (ref. no: 930/
a/06/CPCSEA).
Table 4 Effect of a single dose administration of CBZ SLN on reducing the duration of epileptic phases in Maximal
Electric Shock (MES) model









1 Flexion 1.167 ± 0.1667 Nil Nil (P<0.05) significant
2 Extension 26.50 ± 1.607 0.0 ± 0 0.0 ± 0 (P<0.05) significant
3 Clonus 18.83 ± 0.7923 15.83 ± 2.787 4.667± 1.211 (P<0.05) significant
4 Stupor 72 ± 2.828 35.67 ± 6.377 24.33 ± 7.528 (P<0.05) significant
5 Recovery Recovered Recovered Recovered significant
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Maximal electroshock seizures were induced by an elec-
troconvulsiometer (INCO, Ambala, India). The electrical
stimulus (150 mA, 0.2 sec duration) was applied
through ear electrodes. On giving the shock in normal
animals, it should have a profile of tonic flexion, exten-
sion followed by clonus. Animals were selected by giv-
ing the shock 24 hours before the day of experiment.
Animals that have shown all the three phases of convul-
sions were selected for the study. Eighteen rats were
divided randomly into 3 groups (n = 6). Group I animals
(control) were received 1 ml of 1% tween80/100mg
body weight. Group II, standard reference group,
received 1 mg/100 mg of 1% tween80/100mg, while
Group III, test group received 1 ml of aqueous disper-
sion of CBZ SLN/100 mg body weight. The post exten-
sion phase in standard and test has greatly reduced.
From The ANOVA analysis it is shown that test and
standard groups has shown faster recovery compared to
control. The assessment of the extension/flexion (E/F)
ratio in MES model has been documented as a major
end point used to assess the antiepileptic potentials of
drugs effective in generalized tonic–clonic (grandmal)
seizures. Pure CBZ is used as standard drug in MES
model, which primarily act by blocking voltage-
dependent Na + channels. The experiments were con-
ducted one hour after oral administration.Isoniazid (INH) induced convulsions
The animals were divided in to three groups of 6 each.
Group I was maintained as control and received 1%
tween 80, Group II was maintained as standard received
pure CBZ and Group III were received CBZ optimised
SLN formulation. One hour after administration of drug
dose INH at dose of 300 mg was administered, the rats
were kept in isolated chamber during the next 120 minTable 5 Effect of a single dose administration of CBZ SLN on
epileptic model
INH Induced method Control (Mean± SEM) (Min) Standard
Time for onset of convulsions 28 ± 1.195 58.17 ± 6.6the occurrence of clonic seizures, tonic seizures and
death is recorded. The percentage of seizures or death
occurring in the control group taken as 100%.The sup-
pression of these effects in the treated groups is calcu-
lated as percentage of controls.
Results and discussion
SLNs were prepared by solvent injection technique
which relies on the rapid diffusion of solvent across the
solvent–lipid interface with aqueous phase; hence the
rate of diffusion of organic solvent through the interface
seems to be critical parameter for particle size determin-
ation. In the present work ethanol was selected as mis-
cible solvent due to its solubilising potential for
tristearin, and phospholipon. The smaller particle size is
achieved due to addition of tween 80 and phospholipon
in the organic phase.
FT-IR spectroscopy
FT-IR spectroscopy was employed to obtain conform-
ational information about the lipid molecules and it is
used to investigate the interactions between lipid, drug
and other excipients. From the FT-IR spectra of pure
drug, optimised formulation and physical mixture it is
confirmed that there are no particular interactions be-
tween the lipids and drug (Figure 1). Interpretation of
FT-IR spectra of CBZ SLN was done the functional
peaks are tabulated in Table 1. The presence of charac-
teristic peaks of CBZ physical mixture as well as formu-
lation reveals that the drug remains intact in the
formulation without any interactions.
Differential scanning calorimetry (DSC)
In the development of SLNs the confirmation of desired
physical state of matrix lipid is of crucial importance
which can be determined by the DSC. When the DSCreducing the duration of epileptic phases in INH indused
(Mean± SEM) (Min) Test (Mean± SEM) (Min) Significance
76 135.0 ± 25.10 (P<0.05) significant
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are compared the difference in the position and shape of
the signals are usually observed. Figure 2 shows DSC
curves of CBZ tristearin (TS), physical mixture and
CBZ-SLN. The physical mixture DSC thermogram of
CBZ indicated that there were no interaction between
the drugs and excipients which can be accessed from the
peaks in Figure 2. The DSC thermogram of CBZ SLN
did not show melting point for CBZ which is 172°C,
which is close to the value reported in literature hence
the procured drugs are in pure state. CBZ SLNs did not
show the melting peak for the CBZ around 172°C. This
shows that CBZ was not in crystalline state but it is in
amorphous state.SEM
The SEM photograph (Figure 3) of optimised formula-
tion reveals that SLNs were spherical and moderately
uniform.Entrapment efficiency of CBZ CT SLNs
The EE of the fabricated batches was in the range of
48.84% to 66.7% the total drug content and free dug
content of the 3 formulations are shown in the following
Table 2.Particle size determination
Figure 4 showed, narrow distribution width and consid-
erable narrow particle size for SLNs prepared by solvent
injection method and confirming the good dispersion
quality. The measurement of zeta potential allows for
prediction about the storage stability of colloidal parti-
cles, as the particle aggregation will be less to the
charged particles. For the prepared SLNs the Zeta Po-
tential (mV): particle size and polydispersity index are
tabulated in Table 3.In-vitro diffusion studies
Modified Franz diffusion cells with dialysis membrane
were used in our study. This dialysis membrane allowed
the transfer of drug immediately in to receiver compart-
ment. The % drug release of CBZ from different formu-
lation of SLNs is depicted in Figure 5. The formulation
F3 showed 66.7% of drug was released from SLNs in 24
hours.Antiepileptic activity
MES method In this model, CBZ-CT SLNs have shown
better activity compared to standard and control
(Figure 6). The time for onset of convulsions in CBZ
SLN s treated group took more time compared to test
and standard. Reported in Table 4.INH method
In this model, CBZ SLNs has shown better activity com-
pared to standard and control. The time for onset of
convulsions in the CBZ SLNs has taken more time com-
pared to test and standard. Reported in Table 5.
Conclusion
In the present work CBZ a lipophilic drug when incor-
porated in to Chitosan SLN shows controlled release of
the drug from formulations. The results obtained in this
work suggest that SLN with chitosan have a great poten-
tial for delivery of CBZ due to their high encapsulation
efficiency, high physical stability. The combination of
chitosan with SLN can improve the SLNs properties as
carrier for CBZ because the SLN-chitosan-CBZ exhib-
ited an improved anti epileptic activity when compared
against CBZ in the treatment of seizures.
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